What science discovers, what art creates. These have economic weight before anyone has priced them.

The US market does not respond to what a technology can do in principle. It responds to what it understands, what it can price, and what it can act on. Before a deal process begins, the asset must be legible. We build that translation: how it positions, who the right counterparties are, and what a credible path to market looks like from where the client stands now.

• US market entry strategy for life science and creative enterprises
• Partner identification and counterparty mapping
• Asset positioning and commercial narrative development
• Competitive landscape analysis across sectors

A contract can be built to protect what matters, or it can transfer risk in ways that are not yet visible. We manage the full arc of cross-border transactions from the first conversation through term sheet, due diligence, and close. Licensing agreements, co-development arrangements, co-production structures. The underlying asset may be scientific or creative. The discipline of execution is the same.

• Licensing and co-development deal negotiation
• Co-production and creative IP deal structuring
• Term sheet drafting and counterparty management
• Japanese–US cross-border transaction management

The structure through which capital enters a project determines how much of the original work survives the process. We advise on the design of investment vehicles and production entities: fund architecture, LLC formation, and investor engagement for both life science ventures and creative productions. Structure is not administrative. It is where integrity is either protected or lost.

• Investment fund architecture and offering structure
• Production entity and LLC formation
• Investor relations and capital raising advisory
• Cross-border capital structure for Japanese–US ventures